Jefferies Financial Group Upgrades ICU Medical (NASDAQ:ICUI) to Strong-Buy

ICU Medical (NASDAQ:ICUI) was upgraded by Jefferies Financial Group to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

Other equities analysts also recently issued reports about the stock. KeyCorp decreased their price objective on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a report on Monday, April 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd. Piper Sandler decreased their price objective on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Finally, Wall Street Zen downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, ICU Medical currently has a consensus rating of “Buy” and a consensus target price of $169.00.

ICU Medical Price Performance

Shares of ICUI opened at $123.07 on Thursday. ICU Medical has a 1-year low of $107.00 and a 1-year high of $160.29. The company has a market cap of $3.08 billion, a price-to-earnings ratio of 6,156.58, a PEG ratio of 1.72 and a beta of 0.74. The company’s fifty day simple moving average is $128.93 and its 200 day simple moving average is $138.35. The company has a current ratio of 2.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, February 19th. The medical instruments supplier reported $1.91 EPS for the quarter, beating the consensus estimate of $1.68 by $0.23. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. The firm had revenue of $535.94 million for the quarter, compared to the consensus estimate of $541.20 million. During the same period in the previous year, the company earned $2.11 earnings per share. The company’s quarterly revenue was down 14.1% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, research analysts forecast that ICU Medical will post 6.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ICU Medical

Several institutional investors and hedge funds have recently modified their holdings of ICUI. Hilton Head Capital Partners LLC acquired a new position in shares of ICU Medical in the fourth quarter valued at about $32,000. Covestor Ltd grew its stake in shares of ICU Medical by 70.7% in the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock valued at $68,000 after acquiring an additional 236 shares in the last quarter. Strs Ohio grew its stake in shares of ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after acquiring an additional 300 shares in the last quarter. Rockefeller Capital Management L.P. grew its stake in shares of ICU Medical by 21.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 146 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of ICU Medical in the fourth quarter valued at about $120,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.